Savara Presents New Clinical Data for Molgramostim in aPAP Patients

Savara Inc. presented new clinical data for its lead product candidate, molgramostim inhalation solution, focusing on patients with autoimmune pulmonary alveolar proteinosis (aPAP) and mild diffusion impairment. This data enhances the understanding of the treatment's clinical profile as it is currently in Phase 3 development for aPAP. The presentation took place at a recent industry event.